Aromatase inhibitors for the endocrine adjuvant treatment of breast cancer.
Ravdin
Peter
P
Department of Medical Oncology, University of Texas Health Science Center, San Antonio, TX 98284-7884, USA. peter@oncology.uthscsa.edu
D000077384:Anastrozole; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D047072:Aromatase Inhibitors; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000517:prevention & control; D017024:Chemotherapy, Adjuvant; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D009570:Nitriles / Q000627:therapeutic use*; D017698:Postmenopause; D013629:Tamoxifen / Q000627:therapeutic use*; D014230:Triazoles / Q000627:therapeutic use*
D016588:Anticarcinogenic Agents; D047072:Aromatase Inhibitors; D004791:Enzyme Inhibitors; D009570:Nitriles; D014230:Triazoles; D013629:Tamoxifen; D000077384:Anastrozole